Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: www.sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

9times Feb. 4 at 7:31 PM

$SLS closing this one out. - not one of the many bears on here have been able to support this supposition. There is No evidence to support a median survival past ~ 8 months for control.

0 · Reply

Artorious Feb. 4 at 7:26 PM

$SLS shares > options

1 · Reply

SellasgpsDormantBAT9 Feb. 4 at 7:23 PM

$SLS I have combed through Pfizer’s entire cancer pipeline. Only way to way to deliver 8 cancer Breakthroughs by 2030, Pfizer have to close a deal with a Co. about to deliver the biggest breakthrough in cancer in past 4 decades SLS now to have 8 Breakthrough treatments on the market by 2030! ✌️🙏❤️‍🩹

1 · Reply

FlockOfSeagulls Feb. 4 at 7:20 PM

$SLS The predefined HR bar is now mathematically unreachable. https://chatgpt.com/share/69839b9c-97d0-8003-9fdb-507bffb185e6

1 · Reply

MetalFistSlip Feb. 4 at 7:17 PM

$SLS whole market is taking a dump today it seems This is why it’s good we had our green day yesterday atleast helping us stay consolidated.

0 · Reply

kiwigram Feb. 4 at 7:17 PM

$SLS look at the sell wall at $4.01 😅

0 · Reply

lilBobbyBagholder Feb. 4 at 7:14 PM

$SLS why are so many bios taking a big dump today?

3 · Reply

Fishbanger51 Feb. 4 at 7:13 PM

$SLS 54/63 is 85%...nearly all may mean 0 or 1 bat left

0 · Reply

SellasgpsDormantBAT9 Feb. 4 at 7:11 PM

$SLS Pfizer # 1 Suitor on my list. 👇 Albert Bourla Today: Chairman and Chief Executive Officer, Pfizer 5h: A year ago, we introduced our ambition to deliver eight cancer breakthroughs by 2030. That still drives everything we do in the space: pushing science forward, accelerating development with Al, and working with partners to deliver hope to patients around the world. ✌️🙏❤️‍🩹

0 · Reply

MetalFistSlip Feb. 4 at 7:09 PM

$SLS $SLS Does anyone have the graph of the institutions invested in SLS increasing over the years? I seem to have lost it. Cheers 🥂

1 · Reply

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Dec 29, 2025, 8:35 AM EST - 5 weeks ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

Dec 7, 2025, 6:00 PM EST - 2 months ago

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Oct 29, 2025, 5:36 PM EDT - 3 months ago

SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript

Oct 27, 2025, 8:30 AM EDT - 3 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Aug 19, 2025, 9:18 PM EDT - 6 months ago

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

Aug 7, 2025, 8:30 AM EDT - 6 months ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 7 months ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 5, 2025, 8:45 AM EDT - 8 months ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 8 months ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 9 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 9 months ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 9 months ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 8:45 AM EDT - 10 months ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 10 months ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2025, 8:45 AM EDT - 10 months ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 31, 2025, 3:03 PM EDT - 11 months ago

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

Mar 20, 2025, 4:05 PM EDT - 11 months ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 20, 2025, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 1 year ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 1 year ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 1 year ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 1 year ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 1 year ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:35 AM EDT - 1 year ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 19, 2024, 1:49 PM EDT - 1 year ago

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

Mar 28, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 26, 2024, 7:35 AM EDT - 2 years ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 2 years ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 2 years ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 1, 2024, 8:30 AM EST - 2 years ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Feb 29, 2024, 8:00 AM EST - 2 years ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Feb 6, 2024, 8:30 AM EST - 2 years ago

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

9times Feb. 4 at 7:31 PM

$SLS closing this one out. - not one of the many bears on here have been able to support this supposition. There is No evidence to support a median survival past ~ 8 months for control.

0 · Reply

Artorious Feb. 4 at 7:26 PM

$SLS shares > options

1 · Reply

SellasgpsDormantBAT9 Feb. 4 at 7:23 PM

1 · Reply

FlockOfSeagulls Feb. 4 at 7:20 PM

$SLS The predefined HR bar is now mathematically unreachable. https://chatgpt.com/share/69839b9c-97d0-8003-9fdb-507bffb185e6

1 · Reply

MetalFistSlip Feb. 4 at 7:17 PM

$SLS whole market is taking a dump today it seems This is why it’s good we had our green day yesterday atleast helping us stay consolidated.

0 · Reply

kiwigram Feb. 4 at 7:17 PM

$SLS look at the sell wall at $4.01 😅

0 · Reply

lilBobbyBagholder Feb. 4 at 7:14 PM

$SLS why are so many bios taking a big dump today?

3 · Reply

Fishbanger51 Feb. 4 at 7:13 PM

$SLS 54/63 is 85%...nearly all may mean 0 or 1 bat left

0 · Reply

SellasgpsDormantBAT9 Feb. 4 at 7:11 PM

0 · Reply

MetalFistSlip Feb. 4 at 7:09 PM

$SLS $SLS Does anyone have the graph of the institutions invested in SLS increasing over the years? I seem to have lost it. Cheers 🥂

1 · Reply

OnTheBalance Feb. 4 at 7:09 PM

$SLS ok Science folks.. help me out here.. NEARLY ALL 80% is NOT "nearly All" What does that NEARLY ALL represent re GPS?

1 · Reply

Bullrunners Feb. 4 at 7:05 PM

$SLS end up green!

0 · Reply

Slstothamoon Feb. 4 at 7:03 PM

$SLS what if you sell tomorrow and the halt news or BO news it tomorrow? Don't be that person Just buy and don't

0 · Reply

Bio_buyout Feb. 4 at 7:02 PM

$SLS The only minor positivity from today is we now have 160 institutions investing in Sellas. Let's see if we can get this to 175 in the next 10 days. My money is all in with Angelos!

0 · Reply

Kuzihunt Feb. 4 at 7:00 PM

$SLS Thanks for the cheapies!

0 · Reply

diagio Feb. 4 at 7:00 PM

$SLS Ouch what happened bulls? Moon landing delayed again? 😂

2 · Reply

SqueeziChamber Feb. 4 at 6:58 PM

If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ limited spots $GLDG $SLS $MBLY $XAIR //

0 · Reply

OnTheBalance Feb. 4 at 6:58 PM

$SLS @zyskowiedza the truth is that neither he, nor the BOD care if little retail Timmy who bought a few days ago stays or leaves. What they are interested in is to ensure that Private Wealth and Family Offices gather a reasonable chunk of shares as they will be more stable in the weeks ahead as the real Price Discovery occurs prior to BO information beginning to show up. It is a way to manage volatility when the stock goes into double digits, when volatility will go way way up. Can't really blame them. There are several strategists guiding Sellas BOD at this time. Some of them like LZ on LinkedIn have worked on other projects with John Varian. They know what they are doing.

0 · Reply

Kenny40000 Feb. 4 at 6:57 PM

$SLS missed SSR designation by 0.25%

0 · Reply

georgeqi Feb. 4 at 6:55 PM

$SLS to me, this "ad infinitum.." may boost that remaining 20% non responsors as well based on latest ceo "near all.." comment..

0 · Reply

Texout Feb. 4 at 6:54 PM

$SLS added 200k

1 · Reply

GpsForTheWin009 Feb. 4 at 6:53 PM

$SLS its already broke down lololololol

2 · Reply

Market Cap	537.01M
Revenue (ttm)	0.00
Net Income (ttm)	-30.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,463,369
Avg Vol	8,978,764
Day's Range	N/A - N/A
Shares Out	142.44M
Stochastic %K	42%
Beta	2.26
Analysts	Strong Sell
Price Target	$6.83